The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review

Figure 3

Receptors or cellular targets on liver cells for nanoparticles active targeting to the liver. (a) Hepatocyte, (b) hepatocellular carcinoma cell, (c) hepatic stellate cells (HSC), (d) Kupffer cell, and (e) endothelial cells (reproduced from [15] with permission from the Royal Society of Chemistry).